Dr. Martin Fehr
Medizinische Onkologie und Hämatologie · Dept. I
INCMOR0208-301: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED, MULTICENTER TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF TAFASITAMAB PLUS LENALIDOMIDE IN ADDITION TO RITUXIMAB VERSUS LENALIDOMIDE IN ADDITION TO RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL) GRADE 1-3A OR R/R MARGINA
Apr 20, 2022Doppel-blind, Placebo-kontrollierte, randomisierte Phase 3 Studie zur Evaluation eines zusätzlichen klinischen Benefits durch die Zugabe des CD19-Antikörpers Tafasitamab zu Rituximab-Lenalidomid bei Patienten mit rezidiviertem/refraktärem Follikuläre...
Clinical Studies - Apr 20, 2022 - Dec 31, 2025
Ongoing
Project leader: Fehr Martin
Members: Bürki Ramona
CAR T- Cell Register
Jul 30, 2021EBMT Registry data processing framework
Clinical Studies - Jul 30, 2021 - Dec 31, 2026
Ongoing
Project leader: Fehr Martin
Members: Breuss Kim, Müller Fiona
Assessing a ctDNA and PET-oriented therapy in patients with DLBCL multicenter, open-label, phase II trial
Jun 8, 2021Despite advances in the clinical care of patients with DLBCL and in understanding the biology of this disease, cure rates have remained the same since the introduction of rituximab to CHOP chemotherapy, and RCHOP chemoimmunotherapy remains the standa...
Clinical Studies - Jun 8, 2021 - Dec 31, 2099
Ongoing
Project leader: Fehr Martin
Members: Harder Anja, Quinter Janine
INCMOR0208-301
Apr 20, 2021A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF TAFASITAMAB PLUS LENALIDOMIDE IN ADDITION TO RITUXIMAB VERSUS LENALIDOMIDE IN ADDITION TO RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY...
Clinical Studies - Apr 20, 2021 - Dec 31, 2099
Ongoing
Project leader: Fehr Martin
Members: Bürki Ramona, Müller Fiona
A Study to Evaluate Imetelstat (GRN163L) in Transfu-sion-Dependent Subjects with IPSS Low or Intermedi-ate-1 Risk Myelodysplastic Syndrome (MDS) that is Re-lapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment
Mar 15, 2021A Study to Evaluate Imetelstat (GRN163L) in Transfu-sion-Dependent Subjects with IPSS Low or Intermedi-ate-1 Risk Myelodysplastic Syndrome (MDS) that is Re-lapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment
Clinical Studies - Mar 15, 2021 - Apr 7, 2030
Ongoing
Project leader: Silzle Tobias
Members: Driessen Christoph, Fehr Martin, Hitz Felicitas, Lehmann Thomas
EMCL-Registry of the European Mantle Cell Lymphoma study group
Dec 20, 2019Klinisches Register des „Europäischen Mantelzelllymphom Netzwerk (EMCL)“. Erfassung von Patienten mit neu diag-nostiziertem oder rezidiviertem Mantelzelllymphom
Clinical Studies - Dec 20, 2019 - Dec 20, 2025
Ongoing
Project leader: Fehr Martin
EMCL-Registry of the European Mantle Cell Lymphoma study group
Dec 20, 2019
Clinical Studies - Dec 20, 2019 - Dec 31, 2030
Ongoing
Project leader: Fehr Martin
Members: Steiner Marianne
EMCL-Register Lymphoma
Dec 20, 2019THE REGISTRY OF THE EUROPEAN MANTLE CELL LYMPHOMA STUDY GROUP FOCUSSING ON INDOLENT MCL AND RELAPSED MCL
Clinical Studies - Dec 20, 2019 - Dec 31, 2099
Ongoing
Project leader: Fehr Martin
Members: Munz Jeannine, Müller Fiona
IELSG 45
Jun 7, 2019A randomized, open-label, multicentre, two-arm phase III comparative study assessing the role of involved mediastinal radiotherapy after Rituximab containing chemotherapy regimens to patients with newly diagnosed Primary Mediastinal Large B-Cell Lymp...
Clinical Studies - Jun 7, 2019 - Dec 31, 2099
Ongoing
Project leader: Fehr Martin
Members: Kern Julia, Müller Fiona
MK-3475-495: KeylmPaCT
Dec 12, 2018A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab- (MK-3475, SCH 900475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (KEYNOTE-495; KeyImPaCT).
Clinical Studies - Dec 12, 2018 - Dec 31, 2099
Ongoing
Members: Fehr Martin, Kern Julia, Müller Fiona
TRIANGLE
Feb 20, 2018Autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing iNduction in Generalized mantle cell Lymphoma – a randomized European MCL Network trial.
Clinical Studies - Feb 20, 2018 - Dec 31, 2099
Ongoing
Project leader: Fehr Martin
Members: Demmer-Steingruber Ruth, Müller Fiona
SAKK 30/15; HOVON 135: A randomized phase II multicenter study to assess the to erability and efficacy of the addition of ibrutinib to 10-day decitabine in UNFIT (i.e. HCT-CI ≥ 3) AML and high risk myelodysplasia (MDS) (IPSS-R > 4.5) patients aged ≥ 66 years. A study in the frame of the masterprotocol of parallel randomized phase II studies in UNFITolder AML/high-risk MDS patients
Oct 27, 2016This is a prospective, open label, multicenter study that is conducted in the frame of a masterprotocol with multiple parallel randomized phase II arms. The scheme of this design consists of one arm with the standard treatment for AML (the 10-day dec...
Clinical Studies - Oct 27, 2016 - Jul 31, 2018
Automatically Closed
Project leader: Fehr Martin
MK-3475-091; PEARLS
Mar 30, 2016A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy (PEARLS)
Clinical Studies - Mar 30, 2016 - Dec 31, 2099
Ongoing
Project leader: Fehr Martin
Members: Demmer-Steingruber Ruth, Müller Fiona
Merck EORTC 1325 / MK-3475-054 - Adjuvant immunotherapy with anti-PD-1 monoclonal anti-body Pembrolizumab (MK-3475) versus placebo after complete resection of high-risk Stage III melanoma: A ran-domized, double- blind Phase 3 trial of the EORTC Mela-noma Group
Mar 1, 2016This is an international, double-blinded, placebo-controlled randomized phase III trial. Enrollment will be a multi-step process. Randomization (placebo vs. pembrolizumab) will be performed centrally and will be stratified for the following factors:...
Clinical Studies - Mar 1, 2016 - Mar 1, 2020
Automatically Closed
Project leader: Fehr Martin
MK-3475-054
Feb 15, 2016Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab (MK-3475) versus placebo after complete resection of high-risk Stage III melanoma: A randomized, double- blind Phase 3 trial of the EORTC Melanoma Group.
Clinical Studies - Feb 15, 2016 - Dec 31, 2099
Ongoing
Project leader: Fehr Martin
Members: Hutter Franziska, Müller Fiona
Rituximab with or without Ibrutinib for untreated patients with advanced follicular lymphoma in need of therapy. A randomized, double-blinded, SAKK and NLG collaborative Phase II trial
Oct 15, 2015Der Behandlungsansatz beim FL sah bislang entweder ein zunächst abwartendes Beobachten beim asymptomati-schen Patienten oder aber monotherapeutische Behand-lungen vor, mit dem Ziel, möglichst lange eine gute Le-bensqualität zu erhalten. Für die asymp...
Clinical Studies - Oct 15, 2015 - Dec 31, 2029
Ongoing
Project leader: Hitz Felicitas
Members: Silzle Tobias, Fehr Martin, Fischer Stefanie
Combination of ibrutinib and bortezomib followed by ibrutinib maintenance to treat patients with relapsed and refractory mantle cell lymphoma; a multicenter Phase I/II trial
Sep 9, 2015Das Mantelzelllymphom zeichnet sich durch eine für B-Zell Lymphome vergleichsweise schlechte Prognose aus. Dies erklärt sich durch häufige Rückfälle und dem meist ausgedehnten Krankheitsstadium und höherem Alter (median 60-65 Jahre) bei Diagnosestell...
Clinical Studies - Sep 9, 2015 - Mar 31, 2021
Automatically Closed
Project leader: Driessen Christoph
Members: Hitz Felicitas, Fehr Martin, Hess Urs, Hess Dagmar, Silzle Tobias
HOVON 103 / SAKK 30/10 protocol Tosedostat
Mar 19, 2015A randomized phase II multicenter study with a safety run-in to assess the tolerability and efficacy of the addition of oral tosedostat to standard induction therapy in AML and high risk myelodysplasia (MDS) (IPSS-R risk score > 4.5) in patients aged...
Clinical Studies - Mar 19, 2015 - Mar 19, 2015
Automatically Closed
Project leader: Hess Urs
Members: Hitz Felicitas, Baumann Michael, Driessen Christoph, Fehr Martin, Silzle Tobias
IELSG 37
Sep 25, 2013A randomized, open-label, multicentre, two-arm phase III comparative study assessing the role of involved mediastinal radiotherapy after Rituximab containing chemotherapy regimens to patients with newly diagnosed Primary Mediastinal Large B-Cell Lymp...
Clinical Studies - Sep 25, 2013 - Dec 31, 2099
Ongoing
Project leader: Fehr Martin
Members: Munz Jeannine, Müller Fiona